This Asset Is The Only Winner In 2018

2018 has been a rough year. And late last week, Bloomberg put out a chart that will make you wish you had put all your money on T-bills in the last 11 months.

Source: Bloomberg.

If you take out volatility, this year’s cross-asset performance is the worst in more than a century.

$3 trillion of U.S. stock value has been lost since the market peaked in September. And while tax cuts, record buybacks, strong corporate earnings, and above-trend growth were supposed to keep the bull market running, investors have been met with a punch to the gut as stocks have crashed, defying conventional logic and looking like a precursor of what’s to come.

“That’s the market making a pretty big call on what’s about to come — the cycle is winding itself down finally, after nine years of recovery,” Rich Weiss, chief investment officer and senior portfolio manager of multi-asset strategies at American Century Investments, said. “There is nowhere in the rest of the world that you can look to for help.”

One thing’s for sure, all asset are struggling together. But T-bills have lived up to their reputation: they are the safest, and most even-keeled of all assets. This year, U.S. Treasury bills have generated returns of nearly 20%, more than doubling the returns of the next closest asset—leveraged loans—making them the undisputed champion of 2018.

While T-bills have won this lackluster year, emerging market stocks, the Asia-Pacific region, and oil are the biggest disappointments of the year in absolute terms, according to Bloomberg. Their losses, however, which are in the neighborhood of 10%, appear to be in line with recent years.

According to GMO LLC, with $70 billion in assets under management, we’ll see negative returns across most asset classes adjusted for inflation for the next seven years. But emerging market assets and cash will be the only place for gains.

Source: Bloomberg.
 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More